Lexaria Bioscience Corp. (NASDAQ: LEXX) announced that it will attend the BIO International Convention from June 22-25 in San Diego, CA. The company's attendance at last year's 2025 BIO convention served as a catalyst for its expanded business development (BD) program, which is now delivering positive results. Lexaria intends to build upon this momentum at this year's conference.
“We are experiencing record-high levels of business development and collaboration interest in our DehydraTECH platform, even before the upcoming BIO conference,” said Richard Christopher, CEO of Lexaria Bioscience. “New business relationships require intense energy and scientific evaluation from both prospective partners to discover the best fit possible. We are working tirelessly in this regard with the intent of generating positive developments that we can publicly discuss.”
BIO is the largest convention of its kind, with over 20,000 attendees expected from the global pharmaceutical and biotechnology industries, as well as investors and finance professionals. The 2025 conference featured over 66,000 partnering meetings. Lexaria has already begun reserving meetings and will be fully booked for the event due to strong industry interest in its proprietary DehydraTECH™ drug delivery platform.
BIO is only the latest example of a multi-faceted BD program that Lexaria launched to inform prospective business partners of the benefits of DehydraTECH™. Although confidential information cannot be publicly disclosed, Lexaria’s BD program has already generated collaborative and potential business partnering discussions with a range of companies, from innovative smaller biotech developers to well-known global pharmaceutical giants.
Lexaria’s BD program continues to develop additional early-stage leads. The company intends to thoroughly evaluate each potential relationship and pursue only those that are in the best interests of its shareholders. Additional information will be made available when appropriate.
About Lexaria Bioscience Corp. & DehydraTECH: DehydraTECH™ is Lexaria’s patented drug delivery formulation and processing platform technology that improves oral drug delivery. It has evidenced the ability to increase bio-absorption, reduce side effects, and deliver some drugs more effectively across the blood-brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 65 patents granted and additional patents pending worldwide. For more information, please visit www.lexariabioscience.com.
